The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2
Abstract Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven overwhelmingly successful and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Daclatasvir (DCV) and sofosbuvir (SFV) are clinically approved against hepatitis C virus (HCV), with satisfactory safety profile. DCV and SFV target the HCV enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited the production of infectious SARS-CoV-2 in Vero cells, in the hepatoma cell line (HuH-7) and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than DCV, SFV and its nucleoside metabolite inhibited replication in Calu-3 cells. Moreover, SFV/DCV combination (1:0.15 ratio) inhibited SARS-CoV-2 with EC50 of 0.7:0.1 μM in Calu-3 cells. SFV and DCV prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Both drugs inhibited independent events during RNA synthesis and this was particularly the case for DCV, which also targeted secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial DCV in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Doses higher than those approved may ultimately be required, but these data provide a basis to further explore these agents as COVID-19 antiviral candidates..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 19. Okt. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.06.15.153411 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018160107 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018160107 | ||
| 003 | DE-627 | ||
| 005 | 20230429085812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200617s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.06.15.153411 |2 doi | |
| 035 | |a (DE-627)XBI018160107 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.06.15.153411 | ||
| 035 | |a (biorXiv)10.1101/2020.06.15.153411 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Sacramento, Carolina Q. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Current approaches of drugs repurposing against 2019 coronavirus disease (COVID-19) have not proven overwhelmingly successful and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Daclatasvir (DCV) and sofosbuvir (SFV) are clinically approved against hepatitis C virus (HCV), with satisfactory safety profile. DCV and SFV target the HCV enzymes NS5A and NS5B, respectively. NS5A is endowed with pleotropic activities, which overlap with several proteins from SARS-CoV-2. HCV NS5B and SARS-CoV-2 nsp12 are RNA polymerases that share homology in the nucleotide uptake channel. We thus tested whether SARS-COV-2 would be susceptible these anti-HCV drugs. DCV consistently inhibited the production of infectious SARS-CoV-2 in Vero cells, in the hepatoma cell line (HuH-7) and in type II pneumocytes (Calu-3), with potencies of 0.8, 0.6 and 1.1 μM, respectively. Although less potent than DCV, SFV and its nucleoside metabolite inhibited replication in Calu-3 cells. Moreover, SFV/DCV combination (1:0.15 ratio) inhibited SARS-CoV-2 with EC50 of 0.7:0.1 μM in Calu-3 cells. SFV and DCV prevented virus-induced neuronal apoptosis and release of cytokine storm-related inflammatory mediators, respectively. Both drugs inhibited independent events during RNA synthesis and this was particularly the case for DCV, which also targeted secondary RNA structures in the SARS-CoV-2 genome. Concentrations required for partial DCV in vitro activity are achieved in plasma at Cmax after administration of the approved dose to humans. Doses higher than those approved may ultimately be required, but these data provide a basis to further explore these agents as COVID-19 antiviral candidates. | ||
| 700 | 1 | |a Fintelman-Rodrigues, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Temerozo, Jairo R. |e verfasserin |4 aut | |
| 700 | 1 | |a de Paula Dias Da Silva, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva Gomes Dias, Suelen |e verfasserin |4 aut | |
| 700 | 1 | |a dos Santos da Silva, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, André C. |e verfasserin |4 aut | |
| 700 | 1 | |a Mattos, Mayara |e verfasserin |4 aut | |
| 700 | 1 | |a Pão, Camila R. R. |e verfasserin |4 aut | |
| 700 | 1 | |a de Freitas, Caroline S. |e verfasserin |4 aut | |
| 700 | 1 | |a Soares, Vinicius Cardoso |e verfasserin |4 aut | |
| 700 | 1 | |a Hoelz, Lucas Villas Bôas |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Tácio Vinício Amorim |e verfasserin |4 aut | |
| 700 | 1 | |a Branco, Frederico Silva Castelo |e verfasserin |4 aut | |
| 700 | 1 | |a Bastos, Mônica Macedo |e verfasserin |4 aut | |
| 700 | 1 | |a Boechat, Núbia |e verfasserin |4 aut | |
| 700 | 1 | |a Saraiva, Felipe B. |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Marcelo Alves |e verfasserin |4 aut | |
| 700 | 1 | |a Rajoli, Rajith K. R. |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrosa, Carolina S. G. |e verfasserin |4 aut | |
| 700 | 1 | |a Vitória, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Letícia R. Q. |e verfasserin |4 aut | |
| 700 | 1 | |a Goto-Silva, Livia |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Marilia Zaluar |e verfasserin |4 aut | |
| 700 | 1 | |a Rehen, Stevens K. |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Bozza, Fernando A. |e verfasserin |4 aut | |
| 700 | 1 | |a Bou-Habib, Dumith Chequer |e verfasserin |4 aut | |
| 700 | 1 | |a Bozza, Patrícia T. |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Thiago Moreno L. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 19. Okt. |
| 773 | 1 | 8 | |g year:2020 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.06.15.153411 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 19 |c 10 | ||
| 953 | |2 045F |a 570 | ||